Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only reported activity is an increase in American Depositary Shares (ADSs) held by specific executives following the reinvestment of dividends paid on April 9, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- Transaction Date: April 17, 2015 (Notification date); April 9, 2015 (Dividend payment date).
- Transaction Type: Re-investment of dividends into ADSs.
- Price per ADS: $47.72.
- Executives Involved: Dr. M M Slaoui (297.838 ADSs) and Mr. D E Troy (400.708 ADSs).
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a).